Cumberland Pharmaceuticals CPIX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$2.86M+55.5% | -$6.44M-1.8% | -$6.33M-12.0% | -$5.65M-56.8% | ||
| $4.15M-15.4% | $4.9M-0.7% | $4.94M-7.4% | $5.33M+15.7% | ||
| $408.32K+35.3% | $301.9K-17.3% | $365.04K-23.2% | $475.26K-35.9% | ||
| $23.19K-18.1% | $28.31K+82.4% | $15.52K+38.1% | $11.24K-67.0% | ||
| $5.24M— | —— | -$3.46M— | —— | ||
| -$2.45M+5.1% | -$2.58M— | —— | —— | ||
| $6.71M— | —— | -$1.41M-110% | $14.54M+2,019% | ||
| $231.83K— | —— | —— | —— | ||
| -$477.64K— | —— | —— | $419.66K+131% | ||
| —— | $0— | —— | $0-100% | ||
| $1.14M0.0% | $1.14M+36.7% | $834.5K— | $0— | ||
| -$836.1K-147% | $1.78M-52.1% | $3.72M— | $0— | ||
| —— | -$1.46M-16.5% | -$1.25M+40.0% | -$2.09M— | ||
| $4.93M— | —— | $6.09M-27.9% | $8.45M+31.2% | ||
| $97.9K+47.3% | $66.46K-76.4% | $281.27K— | —— | ||
| $84.4K-25.5% | $113.25K-34.1% | $171.78K-91.3% | $1.97M+686% | ||
| -$4.99M— | —— | —— | -$14.36M-2,760% | ||
| $263.48K-54.5% | $579.05K-21.8% | $740.53K-29.7% | $1.05M-24.1% | ||
| —— | $36M+3.2% | $34.89M-32.5% | $51.7M-12.4% | ||
| $1.71M-0.2% | $1.72M-47.5% | $3.27M+48.0% | $2.21M+1.9% | ||
| -$6.75M— | —— | -$7.42M— | —— | ||
| —— | —— | —— | —— | ||
| $441.68K-22.4% | $569.23K-12.0% | $647.14K+23.7% | $523.16K+718% | ||
| -$3.53K-124% | $15K-86.2% | $108.82K+3,198% | $3.3K+1,109% | ||
| $23.19K-18.1% | $28.31K+82.4% | $15.52K+38.1% | $11.24K-67.0% | ||
| —— | -$1.46M-16.5% | -$1.25M+40.0% | -$2.09M— | ||
| -$13.22K— | $0— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$836.1K-147% | $1.78M-52.1% | $3.72M— | $0— | ||
| -$477.64K— | —— | —— | $419.66K+131% | ||
| $231.83K— | —— | —— | —— | ||
| $1.14M0.0% | $1.14M+36.7% | $834.5K— | $0— | ||
| —— | —— | —— | —— | ||
| $84.4K-25.5% | $113.25K-34.1% | $171.78K-91.3% | $1.97M+686% | ||
| —— | —— | —— | —— | ||
| $2M— | $0— | —— | —— | ||
| —— | $0— | —— | —— | ||
| —— | $36M+3.2% | $34.89M-32.5% | $51.7M-12.4% | ||
| $62+100% | -$69.7K-201% | $69K+173% | -$94.69K— | ||
| -$836.1K-147% | $1.78M-52.1% | $3.72M— | $0— | ||
| $2M— | $0— | —— | —— | ||
| $1.71M-0.2% | $1.72M-47.5% | $3.27M+48.0% | $2.21M+1.9% | ||
| $4.73K+792% | $530+101% | -$51.9K+97.1% | -$1.8M-4,049% | ||
| —— | —— | —— | $0-100% | ||
| $836.1K-3.2% | $863.32K+7.3% | $804.82K-20.4% | $1.01M— | ||
| -$3.53K-124% | $15K-86.2% | $108.82K+3,198% | $3.3K+1,109% | ||
| $4.83M— | —— | $5.81M-30.4% | $8.35M+30.5% | ||
| $4.83M— | —— | $5.81M-30.4% | $8.35M+30.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cumberland Pharmaceuticals generate?
- Cumberland Pharmaceuticals (CPIX) generated $1.4M in operating cash flow over the trailing twelve months.
- What is Cumberland Pharmaceuticals's free cash flow?
- After $50.3K of capital expenditures, Cumberland Pharmaceuticals's free cash flow was $1.4M over the trailing twelve months, down 23.9% year over year.
- Where does Cumberland Pharmaceuticals's cash flow data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
